Wednesday, July 8, 2026

Patent intelligence · US

US 10973861

Compositions and methods

granted A61KA61K2035/115A61K35/741A61K35/742
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 15
Applicant portfolio 36
Patent details — US 10973861
Jurisdiction
US
Status
granted
Grant date
Apr 13, 2021
Expiration
Apr 8, 2041
Claims
19
CPC classes
A61K, A61K2035/115, A61K35/741, A61K35/742
View on Google Patents ↗

Quick answer

US 10973861 (Compositions and methods) is held by Seres Therapeutics, Inc.. Status: granted. Granted Apr 13, 2021. Expires Apr 8, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
19
CPC classes
A61K, A61K2035/115, A61K35/741, A61K35/742, A61K35/744, A61P

More from Seres Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12409197

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Sep 4, 2045

    granted
  2. US 12214002

    Compositions and methods for treating antibiotic resistance

    Seres Therapeutics, Inc. · Expires Jan 30, 2045

    granted
  3. US 12083151

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Sep 5, 2044

    granted
  4. US 11918612

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Feb 29, 2044

    granted
  5. US 11730775

    Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof

    Seres Therapeutics, Inc. · Expires Aug 17, 2043

    granted
  6. US 11701394

    Compositions and methods for treating cholestatic disease

    Seres Therapeutics, Inc. · Expires Jul 13, 2043

    granted
  7. US 11666612

    Network-based microbial compositions and methods

    Seres Therapeutics, Inc. · Expires Jun 1, 2043

    granted
  8. US 11464812

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Oct 6, 2042

    granted

Frequently asked questions

What is US patent 10973861?

US 10973861 (Compositions and methods) is held by Seres Therapeutics, Inc.. Status: granted. Granted Apr 13, 2021. Expires Apr 8, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10973861?

Seres Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.

When does US 10973861 expire?

Our index shows an expiration date of Apr 8, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.